What this study is
This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group into use of 18 vs 21 gauge needles, also in a 1:1 fashion.
What's being tested
- Radial Access
Intervention · PROCEDURE
Radial Access
- State-of-the-art femoral access with 18 gauge needle
Intervention · PROCEDURE
State-of-the-art femoral access with 18 gauge needle
- State-of-the-art femoral access with 21 gauge needle
Intervention · PROCEDURE
State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
Study details
- Official title
- Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access SIte Complication Reduction in Cardiac Catheterization (REBIRTH)
- Sponsor
- Minneapolis Heart Institute Foundation
- Conditions
- Patient Satisfaction · Vascular Access Complication
- Enrolling
- 3,266 people
- Starts
- 2019-11-15
- Est. completion
- 2028-08-19
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 18 years and older
- Undergoing diagnostic angiography for ischemic symptoms with possible PCI, or undergoing planned urgent or elective PCI
- Has provided informed consent and agrees to participate
- Patients must be equally eligible to undergo cardiac catheterization via radial or femoral access
You can't join if
- Primary PCI for STEMI
- Planned right heart catheterization
- Valvular heart disease requiring valve surgery within 30 days after the index procedure
- Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one)
- Peripheral arterial disease prohibiting vascular access
- Presence of bilateral internal mammary artery coronary bypass grafts
- International normalized ratio ≥1.5 while treated with oral vitamin K antagonists (i.e. warfarin) Receipt of oral factor Xa or IIa inhibitors ≤24 h before procedure
- Planned staged PCI within 30 days after index procedure.
- Any planned surgeries within 30 days after index procedure
- Planned dual arterial access (for example for chronic total occlusion PCI)
- Coexisting conditions that limit life expectancy to less than 30 days
- Positive pregnancy test
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (6)
6 openSan Francisco VA Medical Center
San Francisco, California, United States
- Jeffrey Zimmet, MD, PhD · Contact415-221-4810jeffrey.zimmet@va.gov
- Kendrick Shunk, MD, PhD · Principal investigator
RecruitingMayo Clinic Florida
Jacksonville, Florida, United States
- Federico Simon · Contact904-953-4205Simon.FedericoRey@mayo.edu
- Abdallah El Sabbagh, MD · Principal investigator
RecruitingJoseph Maxwell Cleland Atlanta VA Medical Center
Decatur, Georgia, United States
- Nikki Leslie, RN · Contact404-321-6111nikki.leslie@va.gov
- Kreton Mavromatis, MD · Principal investigator
RecruitingHenry Ford Hospital
Detroit, Michigan, United States
- Michelle Butcher, RN · Contact313-916-7614mbutche1@hfhs.org
- Khaldoon Alaswad, MD · Principal investigator
Not yet recruitingMinneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
- Bavana Rangan, BDS, MPH, CCRP · Contact612-863-3852bavana.rangan@allina.com
RecruitingOklahoma Heart Hospital
Oklahoma City, Oklahoma, United States
- Rebecca Straily, RN · Contact405-608-1287rstraily@okheart.com
- Mazen Abu-Fadel, MD · Principal investigator
Recruiting
Study team
Sponsor
Minneapolis Heart Institute Foundation
Study ID REBIRTH
Principal investigator
Emmanouil Brilakis, MD, PhD
Minneapolis Heart Institute Foundation
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.